{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:50:11Z","timestamp":1761821411357},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.peptides.2018.10.015","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T16:59:30Z","timestamp":1543942770000},"page":"78-84","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models"],"prefix":"10.1016","volume":"112","author":[{"given":"Anneke","family":"Kuipers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert N.","family":"Moll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2018.10.015_bib0005","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/db09-0782","article-title":"AngiotensinI-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice","volume":"59","author":"Bindom","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2018.10.015_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2015.11.017","article-title":"Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro","volume":"2449","author":"Bossi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.peptides.2018.10.015_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EC-16-0098","article-title":"Glucagon-producing cells are increased in Mas-deficient mice","volume":"6","author":"Felix Braga","year":"2017","journal-title":"Endocr. Connect. J."},{"key":"10.1016\/j.peptides.2018.10.015_bib0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1086\/683696","article-title":"Dose-dependent, therapeutic potential of angiotensin-(1-7) for the treatment of pulmonary arterial hypertension","volume":"5","author":"Breitling","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.peptides.2018.10.015_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2014.05.024","article-title":"The ACE2\/Ang-(1\u20137)\/Mas axis can inhibit hepatic insulin resistance","volume":"393","author":"Cao","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0030","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1038\/srep21592","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas axis activates Akt signaling to ameliorate hepatic steatosis","volume":"6","author":"Cao","year":"2016","journal-title":"Sci. Rep."},{"issue":"1 Pt 2","key":"10.1016\/j.peptides.2018.10.015_bib0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","article-title":"Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme","volume":"31","author":"Chappell","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2018.10.015_bib0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81294-5","article-title":"Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db\/db mice","volume":"84","author":"Chen","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.peptides.2018.10.015_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.neuroscience.2017.01.027","article-title":"Angiotensin-(1-7) administration attenuates Alzheimer\u2019s disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation","volume":"346","author":"Chen","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.peptides.2018.10.015_bib0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/diabetes.55.02.06.db05-1022","article-title":"Angiotensin II type 1 receptor blockade improves betacell function and glucose tolerance in a mouse model of type 2 diabetes","volume":"55","author":"Chu","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2018.10.015_bib0055","article-title":"Angiotensin-(1-7) Downregulates Diabetes-Induced cGMP Phosphodiesterase Activation in Rat Corpus Cavernosum","volume":"17","author":"Dhaunsi","year":"2017","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.peptides.2018.10.015_bib0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1042\/CS20130333","article-title":"Modulation of the action of insulin by angiotensin-(1-7)","volume":"126","author":"Dominici","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.peptides.2018.10.015_bib0065","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2018.10.015_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/536426","article-title":"The Effect of the Thioether-Bridged, Stabilized Angiotensin-(1\u20137) Analogue Cyclic Ang-(1\u20137) on Cardiac Remodeling and Endothelial Function in Rats with Myocardial Infarction","volume":"2012","author":"Durik","year":"2012","journal-title":"Int. J. Hypertens."},{"issue":"5 Suppl","key":"10.1016\/j.peptides.2018.10.015_bib0075","article-title":"Angiotensin-(1-7): a new hormone of the angiotensin system","volume":"18","author":"Ferrario","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2018.10.015_bib0080","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition andangiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.peptides.2018.10.015_bib0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2119\/2007-00073.Fraga-Silva","article-title":"The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets","volume":"14","author":"Fraga-Silva","year":"2008","journal-title":"Mol. Med."},{"key":"10.1016\/j.peptides.2018.10.015_bib0090","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1161\/HYPERTENSIONAHA.113.03025","article-title":"Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin\u2019s metabolic action via mas receptor","volume":"63","author":"Fu","year":"2014","journal-title":"Hypertension"},{"issue":"5.47","key":"10.1016\/j.peptides.2018.10.015_bib0095","first-page":"1","article-title":"Furman Streptozotocin-Induced Diabetic Models in Mice and Rats","volume":"70","author":"B.L","year":"2015","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/bip.10532","article-title":"Understanding base-assisted desulfurization using a variety of disulfide-bridged peptides","volume":"71","author":"Galande","year":"2003","journal-title":"Biopolymers"},{"key":"10.1016\/j.peptides.2018.10.015_bib0105","doi-asserted-by":"crossref","first-page":"H1007","DOI":"10.1152\/ajpheart.00563.2014","article-title":"Angiotensin-(1-7) treatment mitigates right ventricular fibrosis as a distinctive feature of diabetic cardiomyopathy","volume":"308","author":"Hao","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0110","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2337\/dc12-0246","article-title":"Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans","volume":"36","author":"Hayashi","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2018.10.015_bib0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.peptides.2014.12.012","article-title":"Regulation of insulin sensitivity, insulin production, and pancreatic \u03b2 cell survival by angiotensin-(1-7) in a rat model of streptozotocin-induced diabetes mellitus","volume":"64","author":"He","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2018.10.015_bib0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3181\/00379727-126-32401","article-title":"Studies of the diabetogenic action of streptozotocin","volume":"126","author":"Junod","year":"1967","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.peptides.2018.10.015_bib0125","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1172\/JCI106180","article-title":"Diabetogenic action of streptozotocin: relationship of dose to metabolic response","volume":"48","author":"Junod","year":"1969","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"10.1016\/j.peptides.2018.10.015_bib0130","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1038\/sj.bjp.0707604","article-title":"Agonist-selective mechanisms of GPCR desensitization","volume":"153","author":"Kelly","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.108.146431","article-title":"Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog","volume":"328","author":"Kluskens","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.peptides.2018.10.015_bib0140","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/0024-3205(86)90565-5","article-title":"Biological activities of angiotensin II-(1-6)-hexapeptide and angiotensin II-(1-7)-heptapeptide in man","volume":"38","author":"Kono","year":"1986","journal-title":"Life Sci."},{"key":"10.1016\/j.peptides.2018.10.015_bib0145","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/379632a0","article-title":"Abnormal splicing of the leptin receptor in diabetic mice","volume":"379","author":"Lee","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2018.10.015_bib0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/jdi.12603","volume":"8","author":"Lei","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.peptides.2018.10.015_bib0155","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1159\/000453172","article-title":"Effects of Diabetic Hyperglycemia on Central Ang-(1-7)-Mas-R-nNOS Pathways in Spontaneously Hypertensive Rats","volume":"40","author":"Li","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.peptides.2018.10.015_bib0160","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-200209000-00035","article-title":"Risk of new-onset diabetes in the Losartan Intervention for endpoint reduction in hypertension study","volume":"20","author":"Lindholm","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.peptides.2018.10.015_bib0165","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3892\/ijmm.2014.1917","article-title":"The angiotensin-converting enzyme 2\/angiotensin (1-7)\/Mas axis protects the function of pancreatic \u03b2 cells by improving the function of islet microvascular endothelial cells","volume":"34","author":"Lu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.peptides.2018.10.015_bib0170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCHEARTFAILURE.113.000672","article-title":"Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db\/db mice by reducing lipotoxicity and inflammation","volume":"7","author":"Mori","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.peptides.2018.10.015_bib0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0026-0495(94)90194-5","article-title":"Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow","volume":"43","author":"Nishina","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.peptides.2018.10.015_bib0180","article-title":"Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?","volume":"6","author":"Padda","year":"2015","journal-title":"J. Diabetes Metab."},{"key":"10.1016\/j.peptides.2018.10.015_bib0185","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1111\/bph.13225","article-title":"Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db\/db mice","volume":"172","author":"Papinska","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0190","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.phrs.2016.02.026","article-title":"Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db\/db) by reducing oxidative stress, inflammation and pathological remodeling","volume":"107","author":"Papinska","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.peptides.2018.10.015_bib0195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/21623945.2015.1131881","article-title":"ACE2\/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity","volume":"5","author":"Patel","year":"2016","journal-title":"Adipocyte"},{"key":"10.1016\/j.peptides.2018.10.015_bib0200","first-page":"91","article-title":"Studies on the diabetogenic action of streptozotocin (NSC-37917)","volume":"29","author":"Rakieten","year":"1963","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.peptides.2018.10.015_bib0205","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/0929866524666170728144357","article-title":"Renin-angiotensin system in diabetes","volume":"24","author":"Rein","year":"2017","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.peptides.2018.10.015_bib0210","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/VHRM.S1905","article-title":"The renin-angiotensin system and diabetes: an update","volume":"4","author":"Ribeiro-Oliveira","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.peptides.2018.10.015_bib0215","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1210\/en.2016-1247","article-title":"The angiotensin-(1-7)\/Mas Axis Improves pancreatic \u03b2-Cell function in vitro and in vivo","volume":"157","author":"Sahr","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2018.10.015_bib0220","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0225","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/01.HYP.0000215289.51180.5c","article-title":"Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice","volume":"47","author":"Santos","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2018.10.015_bib0230","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.peptides.2018.10.015_bib0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00109-013-1087-0","article-title":"Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats","volume":"92","author":"Santos","year":"2014","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.peptides.2018.10.015_bib0240","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2337\/db07-0953","article-title":"Mas deficiency in FVB\/N mice produces marked changes in lipid and glycemic metabolism","volume":"57","author":"Santos","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2018.10.015_bib0245","doi-asserted-by":"crossref","first-page":"E621","DOI":"10.1152\/ajpendo.00054.2015","article-title":"ACE2 deficiency reduces \u03b2-cell mass and impairs \u03b2-cell proliferation in obese C57BL\/6 mice","volume":"309","author":"Shoemaker","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2018.10.015_bib0250","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as acaptopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2018.10.015_bib0255","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2337\/db16-1039","article-title":"Reversal of Bone Marrow Mobilopathy and Enhanced Vascular Repair by Angiotensin-(1-7) in Diabetes","volume":"66","author":"Vasam","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2018.10.015_bib0260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2011.155","article-title":"ACE2 and Ang-(1\u20137) confer protection against development of diabetic retinopathy","volume":"20","author":"Verma","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.peptides.2018.10.015_bib0265","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2018.10.015_bib0270","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.peptides.2010.02.015","article-title":"Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7)","volume":"31","author":"de Vries","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2018.10.015_bib0275","doi-asserted-by":"crossref","first-page":"L341","DOI":"10.1152\/ajplung.00360.2012","article-title":"Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury","volume":"305","author":"Wagenaar","year":"2013","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1573399810666140508121012","article-title":"Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes","volume":"10","author":"Wang","year":"2014","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.peptides.2018.10.015_bib0285","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist","volume":"225","author":"W\u00f6sten-van Asperen","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.peptides.2018.10.015_bib0290","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/HYPERTENSIONAHA.107.102764","article-title":"Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice","volume":"51","author":"Xu","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2018.10.015_bib0295","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/01.HYP.32.3.496","article-title":"Converting enzyme determines plasma clearance of angiotensin-(1-7)","volume":"32","author":"Yamada","year":"1998","journal-title":"Hypertension"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978118301906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978118301906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T19:38:45Z","timestamp":1605555525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978118301906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":59,"alternative-id":["S0196978118301906"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2018.10.015","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2018.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}